KR20150056853A - 당뇨병성 신병증의 치료를 위한 사치환된 피라졸로[4,3-d]피리미딘 화합물의 용도 - Google Patents

당뇨병성 신병증의 치료를 위한 사치환된 피라졸로[4,3-d]피리미딘 화합물의 용도 Download PDF

Info

Publication number
KR20150056853A
KR20150056853A KR1020157010146A KR20157010146A KR20150056853A KR 20150056853 A KR20150056853 A KR 20150056853A KR 1020157010146 A KR1020157010146 A KR 1020157010146A KR 20157010146 A KR20157010146 A KR 20157010146A KR 20150056853 A KR20150056853 A KR 20150056853A
Authority
KR
South Korea
Prior art keywords
amino
pyrazolo
pyrimidine
pharmaceutically acceptable
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157010146A
Other languages
English (en)
Korean (ko)
Inventor
발레리 클레린
제레미 게일
니하드 타미미
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20150056853A publication Critical patent/KR20150056853A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020157010146A 2012-10-23 2013-10-09 당뇨병성 신병증의 치료를 위한 사치환된 피라졸로[4,3-d]피리미딘 화합물의 용도 Ceased KR20150056853A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717429P 2012-10-23 2012-10-23
US61/717,429 2012-10-23
PCT/IB2013/059239 WO2014064566A1 (en) 2012-10-23 2013-10-09 Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy

Publications (1)

Publication Number Publication Date
KR20150056853A true KR20150056853A (ko) 2015-05-27

Family

ID=49765599

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157010146A Ceased KR20150056853A (ko) 2012-10-23 2013-10-09 당뇨병성 신병증의 치료를 위한 사치환된 피라졸로[4,3-d]피리미딘 화합물의 용도

Country Status (15)

Country Link
US (2) US20150274735A1 (https=)
EP (1) EP2911672A1 (https=)
JP (1) JP2015534977A (https=)
KR (1) KR20150056853A (https=)
CN (1) CN104755086A (https=)
AU (1) AU2013336293B2 (https=)
BR (1) BR112015008380A2 (https=)
CA (1) CA2888160A1 (https=)
HK (1) HK1211850A1 (https=)
IL (1) IL238374A0 (https=)
IN (1) IN2015DN03190A (https=)
MX (1) MX2015005004A (https=)
RU (1) RU2015115005A (https=)
SG (1) SG11201502286XA (https=)
WO (1) WO2014064566A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150202576A1 (en) * 2012-12-21 2015-07-23 Lg Electronics Inc. Hollow-fibre membrane having novel structure, and production method therefor

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3925957A4 (en) 2019-02-15 2022-11-02 Tohoku University 1,3-DIOXOLANE DERIVATIVE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
SI1881985T1 (sl) * 2005-05-12 2011-03-31 Pfizer Brezvodne kristalinične oblike N-1-(2-etoksietil)-5(N-etil-N-metilamino)-7-(4-metilpriridin-2-il-amino) -1H-pirazolo(4,3-d)pirimidin-3-karbonil"metansulfonamida
CA2608018C (en) * 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150202576A1 (en) * 2012-12-21 2015-07-23 Lg Electronics Inc. Hollow-fibre membrane having novel structure, and production method therefor

Also Published As

Publication number Publication date
CA2888160A1 (en) 2014-05-01
WO2014064566A1 (en) 2014-05-01
US20160136170A1 (en) 2016-05-19
AU2013336293A1 (en) 2015-04-09
JP2015534977A (ja) 2015-12-07
MX2015005004A (es) 2015-07-17
SG11201502286XA (en) 2015-05-28
CN104755086A (zh) 2015-07-01
HK1211850A1 (en) 2016-06-03
BR112015008380A2 (pt) 2017-07-04
IN2015DN03190A (https=) 2015-10-02
EP2911672A1 (en) 2015-09-02
AU2013336293B2 (en) 2016-05-12
US20150274735A1 (en) 2015-10-01
RU2015115005A (ru) 2016-12-20
IL238374A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
US9808461B2 (en) Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
CA3222841A1 (en) Use of atr inhibitors in combination with parp inhibitors for treating cancer
KR100902799B1 (ko) 키마제 저해제 및 ａｃｅ 저해제를 유효성분으로 함유하는약제
WO2012041771A1 (en) Combination therapy for treating hcv infection
CA3172535A1 (en) Cyclophilin inhibitors and uses thereof
US20160263131A1 (en) Treatment of hepatic fibrosis using an inhibitor of cbp/catenin
WO1997013513A1 (en) At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
KR20150056853A (ko) 당뇨병성 신병증의 치료를 위한 사치환된 피라졸로[4,3-d]피리미딘 화합물의 용도
WO2010097501A2 (en) A combination treatment
US20100249103A1 (en) combination treatment
CN105025895A (zh) 用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物
CA2568436A1 (en) Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
CN103037861A (zh) 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途
CA2946151C (en) Stable solid immunosuppressor composition
JP5883710B2 (ja) Ａｃｅ阻害剤とパンテチンを含有する医薬組成物
JP2012254975A (ja) Ａｃｅ阻害剤とｌ−アルギニンを含有する医薬組成物
JP2007314568A (ja) チオベンズイミダゾール誘導体
WO2013016718A1 (en) Compositions, process of preparation of said compositions and method of treating inflammatory diseases
CN101163705A (zh) 组合产品
KR20170110520A (ko) mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물
HK1182627A (en) Combination therapy for treating hcv infection

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20150420

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160512

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160825

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160512

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I